PMID- 30045280
OWN - NLM
STAT- MEDLINE
DCOM- 20180731
LR  - 20211204
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 30
DP  - 2018 Jul
TI  - Montelukast and budesonide combination for children with chronic cough-variant 
      asthma.
PG  - e11557
LID - 10.1097/MD.0000000000011557 [doi]
LID - e11557
AB  - This study investigated the effectiveness and safety of montelukast combined 
      budesonide (MCB) treatment for children with chronic cough-variant asthma 
      (CCVA).In total, 82 cases of children with CCVA, aged 4 to 11 years were included 
      in this study. All cases received either MCB or budesonide alone between May 2015 
      and April 2017. The primary outcome was lung function, measured by the peak 
      expiratory flow rates (PEFRs) and forced expiratory volume in 1 second (FEV1). 
      The secondary outcome was measured by the clinical assessment score. Furthermore, 
      adverse events (AEs) were also recorded in this study. All outcomes were measured 
      after 8-week treatment.After 8-week treatment, MCB showed greater effectiveness 
      than did budesonide alone in improving the lung function, measured by PEFR V1 
      (P = .02), and FEV1 (P < .01). Similarly, the clinical assessment score also 
      demonstrated significant difference between the 2 groups (P < .05). In addition, 
      no serious AEs occurred in both groups.The results of this study demonstrate that 
      the effectiveness of MCB is superior to budesonide alone in the treatment of 
      children with CCVA.
FAU - Wang, Xiu-Ping
AU  - Wang XP
AD  - Department of Paediatrics, Yan'an People's Hospital, Yanan, China.
FAU - Yang, Lin-Dong
AU  - Yang LD
FAU - Zhou, Jin-Fang
AU  - Zhou JF
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Acetates)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Cyclopropanes)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - 51333-22-3 (Budesonide)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - *Acetates/administration & dosage/adverse effects
MH  - Anti-Asthmatic Agents/administration & dosage/adverse effects
MH  - *Asthma/diagnosis/drug therapy/physiopathology
MH  - Bronchodilator Agents/administration & dosage/adverse effects
MH  - *Budesonide/administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - *Cough/drug therapy/etiology/physiopathology
MH  - Cyclopropanes
MH  - Drug Monitoring/methods
MH  - Drug Therapy, Combination/methods
MH  - Female
MH  - Humans
MH  - Male
MH  - *Quinolines/administration & dosage/adverse effects
MH  - Respiratory Function Tests/methods
MH  - Retrospective Studies
MH  - Sulfides
MH  - Symptom Assessment/methods
MH  - Treatment Outcome
PMC - PMC6078752
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/07/26 06:00
MHDA- 2018/08/01 06:00
PMCR- 2018/07/27
CRDT- 2018/07/26 06:00
PHST- 2018/07/26 06:00 [entrez]
PHST- 2018/07/26 06:00 [pubmed]
PHST- 2018/08/01 06:00 [medline]
PHST- 2018/07/27 00:00 [pmc-release]
AID - 00005792-201807270-00033 [pii]
AID - MD-D-18-03029 [pii]
AID - 10.1097/MD.0000000000011557 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jul;97(30):e11557. doi: 10.1097/MD.0000000000011557.